Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases offers a new therapeutic strategy for triple-negative breast cancer - PubMed

7 hours ago

Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases is a new therapeutic strategy for triple-negative breast cancer (TNBC).
The study involves TNBC patient tissue samples collected with ethical approval from the First Affiliated Hospital of Nanjing Medical University.
Animal experiments were approved by the Animal Ethics Committee of Nanjing Medical University.
Key keywords include Cynaroside, IGF2BP3, N6-methyladenosine, and Receptor tyrosine kinase.
The authors declare no competing interests.
Funding sources include the National Natural Science Foundation of China and other grants.

Hasty Briefsbeta